April 27, 2022 Woodbury, MN — Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) and Kindeva Drug Delivery will work together to advance the clinical program of the Virpax-developed Diclofenac topical spray film (Epoladerm™) in the United States. The product is being studied for the treatment of pain associated with osteoarthritis of the knee. Using Kindeva’s state-of-the-art facilities located in Woodbury, Minnesota, they will bring this product from an existing lab-scale formulation to a phase II and III clinical supply.
“We are excited to continue to advance our product development strategy for Epoladerm by collaborating with a strong partner who has demonstrated expertise in developing and manufacturing complex products for large-scale production,” said Anthony P. Mack, Chairman and CEO of Virpax.
Aaron Mann, CEO of Kindeva Drug Delivery, commented: “We are pleased to support Virpax in their ongoing development of Epoladerm™. This application of our deep expertise with aerosol delivery, transdermal drug development, and combination products is further validation of Kindeva’s strategy.”
Kindeva’s extensive formulation, manufacturing, and device development have paved the way for pharmaceutical innovation, dating back to the first pMDI (pressurized metered-dose inhaler) in 1956. With extensive sustainability efforts underway, Kindeva continues to work as a partner with global pharmaceutical companies on their complex drug and combination product development and commercialization programs.
About Kindeva Drug Delivery
Kindeva is a global contract development manufacturing organization focused on drug-device combination products. Kindeva develops and manufactures products across a broad range of complex drug-delivery formats, including autoinjectors, inhalers, transdermal patches, and microneedles. Its service offering spans early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base in the commercial and health security markets from its nine manufacturing and research and development facilities located in the U.S. and U.K. For more information, please visit www.kindevadd.com.
About Virpax Pharmaceuticals
Virpax a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications is using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval of its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal Molecular-Envelope Technology (MET) enkephalin formulation being developed for the management of acute and chronic pain, including pain associated with cancer, as well as post-traumatic stress disorder (PTSD) under the name PES200. MET technology is also used in AnQlar™, a product candidate to inhibit viral replication caused by influenza or SARS-CoV-2. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of epilepsy in children (rare pediatric disease) and adults. For more information, please visit www.virpaxpharma.com.